Russia’s RDIF sovereign wealth fund and China’s Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia’s Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.
RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.